trending Market Intelligence /marketintelligence/en/news-insights/trending/jdx5USuxDSHF5BkvhqiXUg2 content esgSubNav
In This List

Neurotrope CEO resigns; replacement named

Video

According to Market Intelligence, December 2022

Blog

Insight Weekly: Layoffs swell; energy efficiency PE deals defy downturn; 2023 global risk themes

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook

Blog

Japan M&A By the Numbers: Q3 2022


Neurotrope CEO resigns; replacement named

Neurotrope Inc. appointed Charles Ryan as CEO and director after the resignation of Susanne Wilke.

Ryan's appointment as director is effective Dec. 18, and he will assume the role of CEO effective Feb. 15, 2018.

Currently, Ryan serves as the CEO and president of Orthobond Corp.

Neurotrope develops treatments for Alzheimer's and other neurodegenerative diseases.